February 18, 2016, CAMBRIDGE, Mass. & MADISON, Wis.--(BUSINESS WIRE)--Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing
innovative gene therapies for rare genetic diseases that affect the
central nervous system (CNS), and Waisman Biomanufacturing, a non-profit
gene and cell therapy development and manufacturing group located at the
UW-Madison Waisman Center, (Waisman) announced today that the companies
have entered into an exclusive partnership agreement for the production
of Agilis’ novel gene therapy product, AGIL-FA, for the treatment of
Friedreich’s ataxia (FA).
Subscribe to:
Posts (Atom)
